1 September 2022

1) CTF

GML is working on setting up meetings with the working groups. He will also meet with IB at the FIP congress.

2) Policy updates

FIP

• FIP Council Meeting: GML will bring up his questions about voting (you received an email with all relevant documents on 30/08).

GS1 – open items

• MoU – @ AS did you sign the electronic MoU?
• World Patient Safety Day campaign – SK will share more details during the call
• Quaterly meetings with EAHP – any preferences for specific dates AS?
• GS1 Healthcare in Paris – Speaker profile and permissions | @ AS – please complete

EAHP Survey

• GML will summarise the feedback received so far from ambassadors. Board leads to discuss what should be presented to the rest of the Board at the Board meeting.

NEW | MoU EAHP ESCMID

• @ AS – ESCMID shared a slightly updated version of the MoU (correcting some small things that were incorrect in the template they shared with us). Can this be finalised and signed?

NEW | EHMA – White Paper on Reducing the Environmental Impact of Medicines

• EHMA contacted us today to see if we can contribute to their White Paper and review it by 12 September. Time and capacity could be an issue to engage in this.

NEW | Eurocare (Oslo Declaration Support: united call for policy action to curb alcohol harm)

• Do we want to engage in this by signing up to the declaration (see HERE)

NEW | DG SANTE EXPH Study: Focus Group meeting, 23rd September 2022 – to validate the evaluation results and fill in the gaps

• Should SK join? We declined engaged in the interviews before the summer. 

Open issues – linked to emails shared in the past weeks

• SK will go with AS, PH & DKP through all open issues.

              AS – RPA HMP guidance testing sites (any ideas we should share with RPA; not a must)

             PH – Workforce (preparation ahead of Board meeting) | no feedback from DM; PP would be available for a call

             DKP – no open items (waiting for LB to share his availability for the medical device call)

3) Board meeting

Policy

• Are there any points that you would like to discuss during the Board meeting?

President’s guests – list of invitations

• Category 1 (no changes): ASHP, EPSA, EAFP, ESCP, ESOP, PGEU, FIP
• Category 2 (again patients & doctors?) – CPME usually declines
• Category 3 EU – more than half usually don’t reply; should we focus our invitations a bit more?
• Category 3 International – usually only 5% respond; should we only approach associations that responded to our request in the past 5 years?

4) Consultations – state of play

Due date	Type of consultation	Action
31/08/2022	EMA consultation: Reflection paper on data required in confirmatory studies of medicinal products for the treatment of type 2 diabetes	Shared with EMA leads. Advice from PP – no need to engage.
08/09/2022	EMA consultation: Guidance document on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the Clinical Trial Information System (CTIS)	PP recommends to engage and already shared feedback.
08/09/2022	COM – Medical devices – reclassification of products without an intended medical purpose	Decision by leads not to engage.
08/09/2022	COM – Blood, tissues and cells for medical treatments & therapies – revised EU rules	Waiting for feedback from CP & DM + additional feedback review from AL.
16/09/2022	COM – Digital skills – improving their provision	Waiting for feedback from leads (AS, DKP, TS)
16/09/2022	COM – Digital education – enabling factors for success	Waiting for feedback from leads (AS, DKP, TS)
19/09/2022	COM – EU strategic Framework for Global Health	Draft response will be shared with AS, PH & DKP in the 2nd half of August.

Next policy call ? Wednesday, 21st of September?